Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued faith and trust in Samsung Biologics.

I am pleased to announce that Samsung Biologics posted another record high quarterly financial results. Compared to the same period a year ago, revenue for the first quarter of 2022 increased by 250.5 billion won to 511.3 billion won, and operating profit rose by 102.1 billion won to 176.4 billion won, attributable to stable operation across all three plants and favorable foreign exchange rates. Despite the prolonged COVID-19 pandemic, we continued to build a strong track record of global regulatory approvals ensuring operational excellence and impeccable quality controls. In the anticipated endemic of COVID-19 which would bring our daily life gradually to normal, we will continue to make our best efforts for successful business growth leveraging a strong cumulative backlog and improved manufacturing efficiency across all plants while preparing for the pre-sales and partial operation of Plant 4 in October. In January, to secure future growth engines we announced a capital raise by issuing new shares to existing shareholders and employees. Thanks to our shareholders' strong support, we successfully raised 3.2 trillion won (USD 2.6B), at 639,000 won per share, with a subscription rate of more than 100%. Once again, we would like to sincerely thank our shareholders for supporting us in investing in our sustainable growth.

Of the capital raised, we will invest 1.2 trillion won in purchasing Biogen's (50%-1 share) stake in the Samsung Bioepis joint venture, and the remainder will be spent on expanding additi CDMO capabilities, including Plant 4 construction and securing additional land for Bio Campus II, etc. As a wholly owned subsidiary, Samsung Bioepis will have improved agility and autonomy in decision making to accelerate its biosimilar development capabilities and its future growth plans, including novel drug development, etc. SUC CE Thanks to the strong support and interest from shareholders and investors, Samsung Biologics successfully completed the rights offering. In return, we will continue our efforts to take a great leap forward to diversify our business portfolio for sustainable growth and ultimately become a global biopharmaceutical company with great responsibilities to better serve our clients, shareholders, and ultimately society. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you

Sincerely, John Rim President and CEO, Samsung Biologics